These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 28296824

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Dervieux T, Meyer G, Barham R, Matsutani M, Barry M, Boulieu R, Neri B, Seidman E.
    Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
    [Abstract] [Full Text] [Related]

  • 3. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC, Muktar H, Effken C, Mahajan PB.
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [Abstract] [Full Text] [Related]

  • 4. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP, Hooymans PM, Stockbrügger RW, Neef C, Masclee AA.
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [Abstract] [Full Text] [Related]

  • 6. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 7. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 8. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L, Sharif JA, Galloway P, McGrogan P, Bishop J, Russell RK.
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease.
    Stocco G, Cuzzoni E, De Iudicibus S, Franca R, Favretto D, Malusà N, Londero M, Cont G, Bartoli F, Martelossi S, Ventura A, Decorti G.
    J Clin Gastroenterol; 2014 Jan; 48(1):43-51. PubMed ID: 23787247
    [Abstract] [Full Text] [Related]

  • 11. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
    Nguyen TV, Nguyen TM, Lachaux A, Boulieu R.
    J Clin Pharmacol; 2013 Sep; 53(9):900-8. PubMed ID: 23856979
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
    Wright S, Sanders DS, Lobo AJ, Lennard L.
    Gut; 2004 Aug; 53(8):1123-8. PubMed ID: 15247179
    [Abstract] [Full Text] [Related]

  • 13. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.
    Simsek M, Meijer B, Mulder CJJ, van Bodegraven AA, de Boer NKH.
    Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation.
    Schütz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M.
    Eur J Clin Chem Clin Biochem; 1996 Mar; 34(3):199-205. PubMed ID: 8721407
    [Abstract] [Full Text] [Related]

  • 16. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
    Cuffari C, Hunt S, Bayless T.
    Gut; 2001 May; 48(5):642-6. PubMed ID: 11302961
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
    Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM.
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR.
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [Abstract] [Full Text] [Related]

  • 20. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    Curkovic I, Rentsch KM, Frei P, Fried M, Rogler G, Kullak-Ublick GA, Jetter A.
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1521-31. PubMed ID: 23588559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.